1-[(2R)-tetrahydrofuran-2-ylmethyl]-1H-indole-2,3-dione | 1222555-56-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-[(2R)-tetrahydrofuran-2-ylmethyl]-1H-indole-2,3-dione
• 英文别名: (R)-1-((tetrahydrofuran-2-yl)methyl)indoline-2,3-dione；1-[[(2R)-oxolan-2-yl]methyl]indole-2,3-dione
• CAS: 1222555-56-7
• 化学式: C₁₃H₁₃NO₃
• 分子量: 231.251
• InChiKey: MYZQMLKGVOCOFF-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[(2R)-tetrahydrofuran-2-ylmethyl]-1H-indole-2,3-dione 在 三乙基硅烷 、 水 、 异丙基氯化镁 、 三乙胺 、 三氟乙酸 、 ytterbium(III) triflate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 50.5h， 生成
  参考文献：
  名称：

  Tetracyclic spirooxindole blockers of hNaV1.7: activity in vitro and in CFA-induced inflammatory pain model

  摘要：

  The structure-activity relationship of a new series of tetracyclic spirooxindoles led to the discovery of compound 25a, a potent hNa(V)1.7 blocker with improved ADME properties and in vivo efficacy in the CFA-induced inflammatory pain model.

  DOI：

  10.1007/s00044-012-0180-1
• 作为产物：
  描述：

  靛红 、 alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 1-[(2R)-tetrahydrofuran-2-ylmethyl]-1H-indole-2,3-dione
  参考文献：
  名称：

  Tetracyclic spirooxindole blockers of hNaV1.7: activity in vitro and in CFA-induced inflammatory pain model

  摘要：

  The structure-activity relationship of a new series of tetracyclic spirooxindoles led to the discovery of compound 25a, a potent hNa(V)1.7 blocker with improved ADME properties and in vivo efficacy in the CFA-induced inflammatory pain model.

  DOI：

  10.1007/s00044-012-0180-1

文献信息

• Spiro-oxindole compounds and their use as therapeutic agents
  申请人：Xenon Pharmaceuticals Inc.

  公开号：US08263606B2

  公开（公告）日：2012-09-11

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及螺环-氧吲哚化合物，包括其立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、溶剂化物或前药，用于治疗和/或预防钠通道介导的疾病或病状，如疼痛。
• SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：Chafeev Mikhail

  公开号：US20100137299A1

  公开（公告）日：2010-06-03

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及螺环氧吲哚化合物，包括其立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、溶剂化合物或前药，用于治疗和/或预防钠通道介导的疾病或症状，例如疼痛。
• SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
  申请人：Chafeev Mikhail

  公开号：US20120295897A1

  公开（公告）日：2012-11-22

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及螺环氧吲哚化合物，包括立体异构体、对映体、互变异构体或其混合物；或其药学上可接受的盐、溶剂合物或前药，用于治疗和/或预防钠通道介导的疾病或病症，例如疼痛。
• Spiro-oxindole compounds and their uses as therapeutic agents
  申请人：Chafeev Mikhail

  公开号：US08415370B2

  公开（公告）日：2013-04-09

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  这项发明涉及螺环氧吲哚化合物，包括其立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、溶剂化合物或前药，用于治疗和/或预防钠通道介导的疾病或病症，如疼痛。
• US8263606B2
  申请人：——

  公开号：US8263606B2

  公开（公告）日：2012-09-11